Market Place
Sourcing Support
Tessa Therapeutics dissolves after raising more than $200M
06 Jul 2023 //
FIERCE BIOTECH
Tessa Therapeutics Announces Positive Results from CD30 CAR-T Combination
16 Jun 2023 //
GLOBENEWSWIRE
Tessa Therapeutics™ Off-the-Shelf™ CAR-T Therapy Shows Promising Results
15 Jun 2023 //
GLOBENEWSWIRE
Tessa Therapeutics™ Autologous and Allogeneic Cell Therapy Data
30 May 2023 //
GLOBENEWSWIRE
Tessa Therapeutics Enters into CRADA with the U.S. National Cancer Institute
08 Mar 2023 //
GLOBENEWSWIRE
Tessa Therapeutics Enters CRADA with the National Cancer Institute
08 Mar 2023 //
CONTRACT PHARMA
Tessa`s New Year resolutions is to opt for allogeneic CAR-T
03 Jan 2023 //
FIERCE BIOTECH
Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023
03 Jan 2023 //
GLOBENEWSWIRE
Tessa Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial
12 Dec 2022 //
GLOBENEWSWIRE
Tessa Therapeutics Announces Data from Phase 1 Allogeneic Study Presented at ASH
10 Dec 2022 //
GLOBENEWSWIRE
Tessa Therapeutics, Baylor College of Medicine Execute Agreement
07 Nov 2022 //
GLOBENEWSWIRE
Tessa Therapeutics Announces Three Abstracts Highlighting Data
03 Nov 2022 //
GLOBENEWSWIRE
Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022
01 Nov 2022 //
GLOBENEWSWIRE
Tessa to Participate in 2nd Annual Needham Biotech Private Company 1x1 Forum
06 Oct 2022 //
GLOBENEWSWIRE
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies”
14 Sep 2022 //
GLOBENEWSWIRE
Tessa Therapeutics lures Takeda exec to be its president and CEO
23 Aug 2022 //
THEPHARMALETTER
Tessa Therapeutics Appoints Thomas Willemsen as President and CEO
22 Aug 2022 //
GLOBENEWSWIRE
Tessa Doses 1st Patient in Phase 1b Clinical Trial Investigating TT11
17 Aug 2022 //
GLOBENEWSWIRE
Tessa Tx to Host Scientific Session on CD30 CAR-T targeting of CD30+ Lymphomas
13 Jun 2022 //
GLOBENEWSWIRE
Tessa Therapeutics Completes US$126 Million Financing Led by Polaris Partners
09 Jun 2022 //
GLOBENEWSWIRE
Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
04 Apr 2022 //
GLOBENEWSWIRE
Tessa Announces Positive Data from Phase 2 Trial of Autologous CD30-CAR-T
13 Dec 2021 //
GLOBENEWSWIRE
Tessa Announces Presentation of Autologous and Allogeneic Cell Therapy Data
03 Nov 2021 //
GLOBENEWSWIRE
Tessa Therapeutics Announces Collaboration with A*STAR
22 Jun 2021 //
GLOBENEWSWIRE
Tessa Announces Successful Dosing of First Patient Cohort in Phase I
10 Feb 2021 //
PRNEWSWIRE
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase
10 Feb 2021 //
PRNASIA
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency
18 Jan 2021 //
PRNEWSWIRE
Turning cancer into a curable disease: Immunotherapy expert John Connolly picks
24 Jul 2020 //
ENDPTS
Tessa gets RMAT designation for new CAR-T; FDA adcomm narrowly votes
27 Feb 2020 //
ENDPTS
Tessa Therapeutics Announces USFDA RMAT Designation Granted to its CD30 CAR-T
27 Feb 2020 //
PR NEWSWIRE
Tessa Therapeutics to open manufacturing unit in Singapore
19 Dec 2019 //
BIOSPECTRUMASIA
Tessa Therapeutics and China-Singapore Guangzhou Knowledge City`s Joint Venture
12 Jun 2019 //
PR NEWSWIRE
Tessa Announces Collab with Merck Investigating the Combination of KEYTRUDA
15 Apr 2019 //
PR NEWSWIRE
St. Jude, Tessa Therapeutics announce strategic collaboration
21 Sep 2018 //
BIOSPECTRUM
Former Novo chairman Göran Ando joins the board as Tessa bags $50M in funding
13 Apr 2018 //
ENDPTS
Tessa Therapeutics announces new board member and increase in funding
11 Apr 2018 //
BIOSPECTRUM
Tessa announces opening of recruitment sites across the US for its Ph3
07 Feb 2018 //
BIOSPECTRUM
FiercePharmaAsia—JSR, Orchid, Tessa and more
21 Dec 2017 //
FIERCE PHARMA
Parker Institute-allied Tessa grabs $80M round for its next-gen cancer cell ther
20 Dec 2017 //
ENDPTS
Tessa Therapeutics, Parker Institute partner to jointly advance research
19 Jun 2017 //
PHARMABIZ
Tessa Therapeutics Announces Acquisition of Euchloe Bio
23 Mar 2017 //
DDDMAG
